While limited achievements have been reported in targeted monotherapy in pancreatic cancer harboring CDKN2A loss-of-function genomic alterations [225], a recent pilot study demonstrated efficacy in a small group of PDAC patients with CDKN2A somatic alterations treated with a combination of genomically matched targeted agents [226]. Here, CDKN2A is linked to familial pancreatic carcinoma.